CHARLES DREW UNIVERSITY OF MEDICINE AND SCIENCE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vitamin D in Minorities With Prediabetes

Not Applicable

Completed

Conditions: Pre-diabetes

Interventions: Drug: placebo
Drug: vitamin D

First Posted Date: 2009-04-07

Last Posted Date: 2013-06-14

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 117

Registration Number: NCT00876928

Locations: 🇺🇸
Charles Drew University, Los Angeles, California, United States

Insulin Resistance in Smokers Undergoing Smoking Cessation

Not Applicable

Terminated

Conditions: Cardiovascular Disease
Insulin Resistance

Interventions: Behavioral: Smoking cessation

First Posted Date: 2009-04-07

Last Posted Date: 2014-02-11

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 103

Registration Number: NCT00877513

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Dance Dance Revolution (DDR) in Type 2 Diabetes

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Behavioral: DDR
Behavioral: Treadmill

First Posted Date: 2009-02-25

Last Posted Date: 2013-03-27

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 76

Registration Number: NCT00851019

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Sitagliptin in Combination With Metformin and Sulfonylurea

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin

First Posted Date: 2008-05-30

Last Posted Date: 2014-11-26

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 108

Registration Number: NCT00686634

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Insulin Glargine Versus Twice-Daily NPH

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine at bedtime instead of NPH
Drug: NPH twice-daily

First Posted Date: 2008-05-30

Last Posted Date: 2023-11-02

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 27

Registration Number: NCT00687453

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Exercise Dose-Response on Features of the Metabolic Syndrome

Not Applicable

Completed

Conditions: Insulin Resistance
Metabolic Syndrome
Obesity

Interventions: Behavioral: Low-intensity treadmill exercise
Behavioral: Moderate-intensity treadmill exercise
Behavioral: Non-aerobic stretching exercise

First Posted Date: 2008-05-30

Last Posted Date: 2012-02-28

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 93

Registration Number: NCT00687128

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Insulin Glargine at Bedtime or in AM Versus NPH

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 2 - Insulin glargine QAM
Drug: 1- Insulin glargine QHS
Drug: 3 - NPH insulin QHS

First Posted Date: 2008-05-30

Last Posted Date: 2017-05-22

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 108

Registration Number: NCT00686712

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.

Phase 4

Completed

Conditions: Diabetes
Depression

Interventions: Drug: Placebo
Drug: sertraline

First Posted Date: 2008-02-26

Last Posted Date: 2017-12-12

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 89

Registration Number: NCT00624013

Locations: 🇺🇸
Charles Drew University, Los Angeles, California, United States

Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

Not Applicable

Terminated

Conditions: End Stage Renal Disease (ESRD)

Interventions: Other: placebo
Drug: soluble ferric pyrophosphate (SFP)

First Posted Date: 2008-01-30

Last Posted Date: 2015-08-31

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 11

Registration Number: NCT00604565

Locations: 🇺🇸
RAI, Los Angeles, California, United States
🇺🇸
University of Louisville Kidney Disease Program, Louisville, Kentucky, United States

Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS

Phase 4

Completed

Conditions: Chronic Fatigue Syndrome

Interventions: Drug: Sildenafil (Viagra)
Drug: Placebo

First Posted Date: 2008-01-22

Last Posted Date: 2017-06-27

Lead Sponsor: Charles Drew University of Medicine and Science

Target Recruit Count: 12

Registration Number: NCT00598585

Locations: 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy